PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform that is intended to treat infections in chronic and acute wounds, announced today an agreement with Bayer Australia’s Animal Health division for the development of the Microcyn® Technology for use in the Australian animal market.
